Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Through the acquisition of Genzyme, Sanofi has strongly reinforced its footprint in rare diseases.
Contact
Address: Jl. Jend. A. Yani, Pulo MasJakarta 13210IndonesiaJl. Jend. A. Yani, Pulo Mas. 13210. Jakarta.
Tel. +62 21 478 99 789
Website: http://www.sanofi.co.
Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their…
Over the past three years, Sanofi has significantly expanded its presence in the GCC region, launching 40-50 new products, including treatments for rare diseases and advancements in immunology, diabetes management,…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
Women account for half of the Portuguese labour force, but Portugal lags behind the European average for women in top positions, as a 2023 McKinsey study shows. However, Portuguese pharma…
Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of…
While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific…
A staunch advocate for diversity and inclusion, Helena Freitas today leads the Portuguese affiliate of Sanofi, consistently ranked among the leading pharmaceutical firms in the country. With a focus on…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Sanofi’s Adrien Delamare-Deboutteville describes the access to innovation landscape in Morocco today, how Sanofi is aiming to bolster access in line with the country’s universal healthcare transformation, and the lessons…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the…
See our Cookie Privacy Policy Here
